BioDlink has successfully shipped its first international batch of bevacizumab injection biosimilar to Colombia, working together with Kexing BioPharm. This achievement was marked by a special event with decorated delivery trucks to celebrate the milestone. Bevacizumab is a type of monoclonal antibody that targets vascular endothelial growth factor, and it’s used to treat several types of cancer, including metastatic colorectal cancer and some lung cancers. In 2023, this drug generated over 8.5 billion USD in global sales, showing how important it is in cancer treatments.
Health Technology Insights: Cycle Pharmaceuticals Launches PHYRAGO Tablets in US for Oncology
In July 2025, BioDlink got marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) for its bevacizumab injection. This first shipment, sent about two months after approval, shows how efficiently BioDlink operates and confirms the strength of its platform for commercializing antibodies, along with its high production standards and reliable supply chain. BioDlink’s 50,000-square-meter manufacturing facilities have passed EU Qualified Person audits for antibody drugs and ADCs five times in the past four years, without any major issues. The company has a strong global quality system and has worked on more than 100 clinical projects around the world, including in Europe and the United States.
Health Technology Insights: Color Health, Google Cloud Team Up to Boost Breast Cancer Screening
Kexing BioPharm, which has the global license for bevacizumab in emerging markets, holds GMP certification in China, Colombia, Brazil, Argentina, Egypt, Indonesia, Pakistan, and Thailand. It has also begun regulatory filings in 35 countries, working closely with BioDlink. The GMP certifications in Brazil, Colombia, and Argentina cover the three largest countries in South America, which together have over 71% of the continent’s population. The shipment to Colombia is especially important because the country has a high cancer rate, with 117,620 new cases in 2022, including 11,163 colorectal and 7,196 lung cancer cases. Bevacizumab’s use matches these needs perfectly, making the shipment both timely and significant for patients.
Since signing an international commercialization agreement in early 2022, BioDlink and Kexing BioPharm have developed a complementary and efficient R&D-manufacturing-access model that sets a strong foundation for future launches of other products globally. BioDlink focuses on ensuring reliable manufacturing and supply chain performance, while Kexing BioPharm uses its global network to help with local market access. Both companies are committed to improving global healthcare through their ongoing partnership.
BioDlink continues to follow its philosophy of “Quality First, Innovation Driven, Success Together” and is focused on expanding access to oncology treatments in emerging markets across South America, South Asia, Southeast Asia, and Africa. Their collaboration aims to provide high-quality cancer treatments to a broader global patient population, making sure both innovation and reliable access are prioritized in every market.
Health Technology Insights: IntrinsiQ Enhances Data Tools to Boost Patient Outcomes
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
